A Discussion About a Hematology Career in Industry With Drs. Benjamin Kim and Mark Chao
Dr. Benjamin Kim and Dr. Mark Chao discuss what it's like for a hematologist holding an industry position.
Predicting Responses to Gemtuzumab Ozogamicin
Dr. Raetz looks at the use of gemtuzumab ozogamicin (CO) for the treatment of acute myeloid leukemia in adults and children.
Insightful critiques and informed commentary of important ongoing clinical trials
Dr. Jacobson looks at a study that investigates the safety and efficacy of chimeric antigen receptor (CAR)- T cell therapy with KTE-C19 in combination with the anti-PD-L1 antibody atezolizumab in patients with refractory DLBCL.
Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.
Dr. Keel breaks down a study that looks at the use and effects of two different doses of intravenous iron in patients with chronic kidney disease on hemodialysis.
Dr. Roberts looks at whether chemoimmunotherapy can be improved as a front-line therapy for chronic lymphocytic leukemia in fit patients.
Dr. Linkins covers a study that compares apixaban with no anticoagulants for prevention of a composite of fatal and nonfatal venous thromboembolism in children with a central venous catheter and newly diagnosed ALL, lymphoma or mixed-phenotype acute leukemia.
Drs. Raetz and Kovacsovics cover a trial meant to develop a precision medicine approach for the treatment of AML.
Dr. Moss covers a study that compares the PD-1 inhibitor pembrolizumab with brentuximab vedotin in subjects with relapsed or refractory classical HL.
Dr. Garcia discusses a study that tests a new therapeutic approach with antifibrinolytic agents to chemotherapy-associated thrombocytopenia.
Dr. Abdel-Wahab and Dr. Taylor cover a study that measures the safety of combination ABT-199 and hypomethylating agents in older adults with acute myelogenous leukemia (AML), who are treatment-naive and not eligible for standard induction therapy.
Dr. Cuker and Dr. George discuss a study that evaluates the safety, tolerability, and pharmacokinetics of SPK-9001 in subjects with hemophilia B.
November-December 2017Volume 14, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology